Zobrazeno 1 - 6
of 6
pro vyhledávání: '"John C. Byrd"'
Autor:
Giovanna Merchand-Reyes, Mikayla F. Bull, Ramasamy Santhanam, Maria L. Valencia-Pena, Rakesh A. Murugesan, Aadesh Chordia, Xiaokui-Molly Mo, Frank H. Robledo-Avila, Juan De Dios Ruiz-Rosado, William Edgar Carson, John C. Byrd, Jennifer A. Woyach, Susheela Tridandapani, Jonathan P. Butchar
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionTherapeutic antibodies have become a major strategy to treat oncologic diseases. For chronic lymphocytic leukemia, antibodies against CD20 are used to target and elicit cytotoxic responses against malignant B cells. However, efficacy is o
Externí odkaz:
https://doaj.org/article/2840c3664e3b44e69f5cbcfe156bc02d
Autor:
Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti, Chrysoula Belessi, Neil E. Kay, Frederic Davi, John C. Byrd, Sarka Pospisilova, Jennifer R. Brown, Mark Catherwood, Zadie Davis, David Oscier, Marco Montillo, Livio Trentin, Richard Rosenquist, Paolo Ghia, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Kostas Stamatopoulos, Thomas J. Kipps, Donna Neuberg, Nicholas Chiorazzi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells
Externí odkaz:
https://doaj.org/article/c619ded3a3974ed5becc2e624f138274
Autor:
Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lym
Externí odkaz:
https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Autor:
William G. Wierda, S. M. O'Brien, John C. Byrd, Richard R. Furman, Jeff P. Sharman, Jennifer R. Brown, Paolo Ghia
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f574af02d334e40c95c855964f02d5f
Publikováno v:
Frontiers in Physiology, Vol 6 (2015)
Frontiers in Physiology
Frontiers in Physiology
Tetraspanins belong to a family of transmembrane proteins which play a major role in the organization of the plasma membrane. While all immune cells express tetraspanins, most of these are present in a variety of other cell types. There are a select
Publikováno v:
Frontiers in Physiology, Vol 6 (2015)
Tetraspanins belong to a family of transmembrane proteins which play a major role in the organization of the plasma membrane. While all immune cells express tetraspanins, most of these are present in a variety of other cell types. There are a select
Externí odkaz:
https://doaj.org/article/f821bd2d377b4b5696e20643135fb26c